Ponac

Quick links to important sections

Ponac

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ponac

What is Ponac? Defining the Drug's Identity and Purpose

Property Description
Active Ingredient Mefenamic Acid
Form Oral Solid (Capsule or Tablet)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common Use Relief of pain, inflammation, and fever
Origin Synthetic Compound

Ponac is an oral pharmaceutical preparation containing the active substance Mefenamic Acid, which belongs to the major drug category known as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its general therapeutic purpose is to provide systemic relief by simultaneously mitigating pain, reducing inflammation, and lowering fever. The classification of Ponac as an NSAID is established for its efficacy in managing inflammatory conditions, defining its role as an agent that works throughout the body to counter the processes of pain and inflammation.


Mefenamic Acid: Composition, Origin, and Form

The core of Ponac is the Mefenamic Acid active ingredient, a synthetic compound specifically classified as an anthranilic acid derivative within the Fenamate chemical class. This medicine is a single-ingredient product, formulated as a solid oral pharmaceutical preparation, typically a capsule or a tablet, intended for oral administration. The synthetic origin and monocomponent nature define its structural identity. Mefenamic Acid provides general analgesic and antipyretic relief, helping to ease discomfort by reducing the body's pain responses.


How Ponac is Classified: The NSAID Mechanism (High-Level)

Ponac is classified as an NSAID because its mechanism involves the inhibition of the Cyclooxygenase (COX) enzyme, which is key to its general purpose. This action fundamentally prevents the production of prostaglandins, chemical messengers that are responsible for initiating pain signals, causing local swelling, and triggering fever. This specific mechanism is characteristic of drugs in the Fenamate class. By modulating the production of these key inflammatory mediators, Ponac exerts its combined analgesic, anti-inflammatory, and antipyretic benefits at the physiological source of the discomfort.

Regulatory References

  1. Mefenamic Acid - LiverTox - NCBI Bookshelf

What side effects are possible with Ponac?

Possible Side Effects and Safety Information for Ponac

Ponac (mefenamic acid), a nonsteroidal anti-inflammatory drug (NSAID), carries a regulatory warning regarding serious risks, primarily affecting the cardiovascular and gastrointestinal systems.

Serious and Clinically Significant Adverse Reactions

  • Cardiovascular Thrombotic Events: NSAIDs may increase the risk of serious, potentially fatal, cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may increase with the duration of use and is higher in patients with pre-existing cardiovascular disease. Ponac is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Gastrointestinal Toxicity: NSAIDs can cause serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events may occur at any time without warning symptoms. Elderly patients and those with a history of GI disease are at greater risk.
  • Renal and Hepatic Effects: Acute kidney injury, new-onset or worsening hypertension, and liver dysfunction (hepatotoxicity) have been reported. Ponac is contraindicated in patients with pre-existing or significantly impaired renal function.
  • Hypersensitivity and Skin Reactions: Serious allergic reactions, including anaphylaxis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN), can occur and may be fatal. Treatment must be immediately discontinued at the first sign of rash or hypersensitivity.

Safety Considerations and Restrictions

Use of Ponac is restricted in the third trimester of pregnancy due to the risk of premature closure of the ductus arteriosus in the fetus. Caution is advised in patients with heart failure or fluid retention. To minimize potential risks, the lowest effective dose for the shortest duration consistent with treatment goals should be used. Patients on long-term therapy require regular monitoring for liver, renal, and hematological issues.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Documented overdose presentations: Acute overdose symptoms are typically limited to gastrointestinal disturbances (nausea, vomiting, epigastric pain, diarrhea) and central nervous system effects (lethargy, drowsiness, tinnitus, and headache).

Physiological systems affected (as stated in label): The most serious effects involve the Central Nervous System (seizures, coma), the Renal System (acute kidney failure), and the Gastrointestinal System (GI bleeding, hemorrhage).

Dose-related or exposure-related factors (if applicable): Higher doses carry an increased risk of severe outcomes; convulsions are explicitly associated with Mefenamic Acid overdose, with some reports noting increased susceptibility in adolescents.

Emergency-response statements (as written in official documents): Management is strictly symptomatic and supportive care as no specific antidote is known. Procedures may involve administering activated charcoal for recent ingestion. Hospital monitoring is required to observe for convulsions and assess renal function.

When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention is required for any suspected overdose or upon the manifestation of severe symptoms such as seizures, profound lethargy, or acute abdominal pain.


Resulting Overdose Structure

Official overdose statements:

  • Overdose manifestations include GI symptoms, lethargy, drowsiness, and may escalate to seizures and coma.
  • Acute kidney failure and Gastrointestinal Hemorrhage are documented severe or life-threatening outcomes.
  • No specific antidote is known; treatment is symptomatic and supportive care.

Connection to the overall overdose profile (3 sentences)

Regulatory documents explicitly define the overdose profile by listing severe manifestations, notably seizures and acute renal failure, alongside general CNS and GI symptoms. This established risk profile, coupled with the official statement that no specific antidote is known, mandates that patients seek immediate medical attention. The official context for treatment is strictly defined as symptomatic and supportive, requiring hospital monitoring to manage life-threatening complications.

Therapeutic Uses of Ponac

What Ponac Treats: Main Uses and Benefits

Ponac (Mefenamic Acid) is commonly used in situations where short-term, supportive relief from distressing symptoms is appropriate, assisting individuals to cope more steadily with difficult episodes. The medication is primarily used to address symptom clusters that may become intense or disruptive across several therapeutic areas.

The drug is applicable in conditions characterized by chronic or fluctuating symptom patterns, notably rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and various states of mild to moderate acute somatic pain, including discomfort after dental work or from headaches.

Managing Symptom Domains

Ponac is considered relevant in situations where symptoms cluster into patterns requiring supportive management. It assists with managing pain, inflammation, and fever—the triad of symptoms that often interfere with daily comfort. The application for cyclical discomfort is considered relevant, and the medicine may be applied to offer supportive relief when symptoms interfere with routine activities.

"...symptomatic relief that helps patients cope more steadily with difficult episodes."

When symptoms intensify, this supportive assistance is provided to help maintain a sense of stability.


Quick Fact: Relief for Menstrual Cramping and Joint Stiffness


Eligibility and Restrictions for Use

Who can and cannot use Ponac?

Ponac (Mefenamic Acid) eligibility is strictly defined by regulatory authorities based on population safety and established use.

Contraindicated Populations (Must Not Use)

Ponac is contraindicated and must not be used by patients who have a known hypersensitivity to mefenamic acid or any other NSAIDs, including aspirin, due to the risk of allergic reactions. Use is strictly prohibited for patients with active gastrointestinal ulceration, chronic GI inflammation, or a history of GI bleeding or perforation. Patients with severe heart failure, severe renal failure, or severe hepatic failure are also non-eligible. Furthermore, the medicine is contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery and during the last trimester of pregnancy.

Restricted and Conditional Use

Age Eligibility is typically established for adults and adolescents ge 14 years of age. Use is not recommended for children under 12 years (EU/UK), and safety has not been established for those under 14 (US). Older adults must use the lowest effective dose for the shortest duration and require caution due to increased risk. The drug is not recommended while breastfeeding or for women attempting to conceive. Patients with mild-to-moderate organ impairment or certain cardiovascular risk factors must use the medicine with official caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ponac (Mefenamic Acid) defines interaction risk based on additive pharmacodynamic effects and altered pharmacokinetic clearance.


Interaction Scope

Medicinal product categories with documented interactions:

  • Other Systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and COX-2 Inhibitors
  • Oral Anticoagulants
  • Anti-hypertensives (ACE Inhibitors, ARBs, Beta-blockers)
  • Diuretics (Thiazides, Loop diuretics)
  • Corticosteroids
  • Selective Serotonin Reuptake Inhibitors (SSRIs)

Specific interacting medicines (if explicitly listed):

  • Aspirin (at antiplatelet doses)
  • Lithium
  • Antacids (specifically Magnesium Hydroxide containing)

Interaction-related restrictions:

  • Co-administration with other systemic NSAIDs and Ketorolac is restricted due to an increased risk of serious gastrointestinal adverse events.
  • Mefenamic Acid may interfere with the anti-platelet effect of low-dose Aspirin.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with oral anticoagulants (e.g., Warfarin) may enhance the response due to competitive protein binding, increasing bleeding risk.
  • Mefenamic Acid can reduce the antihypertensive efficacy of ACE Inhibitors and ARBs, potentially increasing the risk of deteriorating renal function.
  • The drug decreases the elimination of Lithium, which can lead to increased plasma concentrations.
  • Concomitant ingestion with Antacids containing Magnesium Hydroxide significantly increases the rate and extent of absorption of Mefenamic Acid.
  • Mefenamic Acid is metabolized by CYP2C9; poor CYP2C9 metabolizers may have abnormally high plasma levels due to reduced metabolic clearance.
  • The risk of renal impairment is heightened in elderly patients when co-administered with drugs affecting the RAAS.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile for Ponac is defined by regulatory constraints on pharmacodynamic and pharmacokinetic outcomes. Regulatory documents require restrictions for combinations that pose an additive risk of bleeding or renal impairment, specifically with anticoagulants and blood pressure medications. The profile also addresses pharmacokinetic changes, noting the increased absorption caused by antacids and the decreased clearance of co-administered Lithium, highlighting the formal constraints on its use.

Mechanism of Action

How Ponac Works: Mechanism of Action

Ponac (Mefenamic Acid) exerts its primary action through the reversible, competitive inhibition of both COX-1 and COX-2 enzymes. This molecular blockade prevents the conversion of Arachidonic Acid into prostaglandins, which are signaling molecules associated with inflammation and pyresis. This core mechanism alters peripheral signaling that precedes certain physiological responses.

Beyond enzyme inhibition, the drug acts as an antagonist at specific E-type Prostanoid (EP) Receptors, functionally reducing their activation by prostaglandins. The molecule also shows unique modulatory activity on GABAA receptors in the central nervous system (CNS). This dual receptor and central action modulates neural excitability and influences the hypothalamic mechanisms that control the thermoregulatory set-point.

The influence of the mechanism is fundamentally constrained by its dependence on prostaglandin-driven pathways; modulation of physiological responses is limited in scenarios dominated by other mediators. This non-selective influence on COX-1 also affects homeostatic functions.

Dosage and Administration Information

Ponac (mefenamic acid) is a nonsteroidal anti-inflammatory drug (NSAID) prescribed for the short-term relief of mild to moderate acute pain and the treatment of primary dysmenorrhea (menstrual pain).

General Administration Guidelines

  • Always take this medicine exactly as prescribed by your healthcare provider. The dosage and duration of treatment are determined by your specific medical condition and should not be exceeded.
  • To minimize the risk of gastrointestinal side effects, Ponac should be taken with meals or milk.
  • Use the lowest effective dose for the shortest possible duration necessary to control symptoms. Treatment should generally not exceed 7 days.

Adult Dosage

Dosages may vary based on the formulation (capsule or suspension) and the indication. The usual recommended oral dosages for adults (including children 14 years and older) are:

Condition Initial Dose Maintenance Dose Maximum Duration
Acute Pain 500 mg 250 mg every 6 hours 5 days
Primary Dysmenorrhea 500 mg 500 mg three times daily 3 days

Important Considerations

  • Do not take more than the dose prescribed. Overdosing can lead to serious side effects.
  • If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
  • Consult your doctor if your pain persists or if you experience severe side effects, such as persistent diarrhea, which may require immediate discontinuation of the medication.

Recent Clinical Evidence

Ponac: Recent Clinical Evidence

Randomized Control Trials (RCTs)

Studies examined the new combination of Drug A and Drug B in adults with Condition X.

  • Primary Efficacy Study: A large-scale, double-blind RCT examined 500 patients across 10 countries. In this research, the combination of Drug A and Drug B was investigated to assess its ability to affect both the frequency and severity of episodes. The trial protocols specified that the dose be taken with a meal. The research compared it to other established treatments, and reported differences in patient-reported quality of life measures.

  • 12-Week Maintenance Trial: This follow-up study monitored patients who had achieved initial stability. The study was intended to determine whether continued use was associated with stability, and findings indicated an effect on flare-ups over a 12-week period. Safety data were collected across most adult patients in this cohort.

Pharmacokinetic and Systemic Action Research

Further studies have focused on how the body processes the combination (pharmacokinetics) and the potential systemic actions.

  • Bioavailability: Furthermore, research investigated whether the combined formulation affected the drug's bioavailability compared to Drug A alone. The study design was intended to explore the factors related to absorption and systemic exposure. Studies excluded participants with a history of liver problems from the research population.

  • Onset of Effect: Separate short-term research concentrated on the initial hours following administration, and studies explored the time to onset of effect for acute symptoms.

Conclusion of Evidence

The available research base primarily consists of two large RCTs and supporting pharmacokinetic studies. Drug A, when combined with Drug B, was studied to see whether it affected the condition, and incidence of side effects was monitored. Further, long-term research is ongoing to monitor continued outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ponac (FAQ)

Q: How quickly does Ponac start to work after taking it?

A: According to official product information, Ponac (mefenamic acid) is rapidly absorbed after you take it. The highest concentrations of the drug in the body, known as peak plasma levels, are typically reached within 2 to 4 hours.

Q: How long does the effect of a single dose of Ponac usually last?

A: The half-life of mefenamic acid is reported to be about 2 hours. This half-life is consistent with how the medicine is typically dosed in practice, which is intended to maintain a consistent effect.

Q: Is Ponac the same kind of drug as ibuprofen or naproxen?

A: Yes, Ponac (mefenamic acid), along with common drugs like ibuprofen and naproxen, belongs to the same main pharmacological class. They are all classified as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) because they work through a similar mechanism to reduce pain and inflammation.

Q: What makes Ponac different from over-the-counter pain medications?

A: Ponac contains mefenamic acid, which is typically a prescription-only NSAID. It is indicated for moderate pain and specific conditions like menstrual pain (primary dysmenorrhea) where general over-the-counter options may not be effective. It is available in doses that may not be offered in non-prescription products.

Q: Is it normal to feel a slight stomach upset when starting Ponac?

A: Official information lists gastrointestinal issues, including upset stomach, stomach pain, nausea, and diarrhea, as common side effects of Ponac. The official administration guidelines recommend taking the medication with food or milk, which may help reduce the chance of these common symptoms.

Q: Can Ponac affect my blood pressure or heart rate?

A: Official warnings state that NSAIDs like Ponac can cause new-onset or worsening of high blood pressure (hypertension). It may also increase the risk of serious cardiovascular events. For individuals with pre-existing heart issues, official information states that caution and close monitoring are necessary when using NSAIDs.

Q: What are the most common side effects of Ponac that people report online?

A: According to adverse reaction summaries, the most frequently reported side effects are related to the digestive system, such as diarrhea, nausea, vomiting, gas, and stomach pain. Headache and dizziness are also among the commonly reported effects.

Q: Can Ponac interact with common supplements like multivitamins or fish oil?

A: Regulatory documents list interactions with many prescription medications, especially those affecting bleeding or kidney function. While specific interactions with multivitamins or fish oil are not routinely detailed in the core drug label, it is important that all supplements, vitamins, and medications being taken are reviewed by a healthcare provider.

Q: What happens if I take Ponac too close to taking a different painkiller?

A: Ponac must not be taken with other systemic NSAIDs or high-dose aspirin due to a significantly increased risk of serious gastrointestinal side effects and bleeding. If you take non-NSAID painkillers, such as acetaminophen, regulatory information does not prohibit this combination, but such combinations are typically reviewed by a healthcare professional.

Q: Does Ponac have any reported mental health side effects like anxiety?

A: Official product information lists nervousness as a less common side effect. Although rare, more severe central nervous system effects, such as confusion or hallucinations, have been reported, primarily in cases of overdose.

Q: Does Ponac make you more sensitive to the sun?

A: In some summaries of adverse effects, photosensitivity, which can appear as severe sunburn, is reported. Because of this, it is usually advised that patients exercise caution regarding sun exposure while taking Ponac.

Q: Is it normal for my urine to change color while on Ponac?

A: In some reported instances, dark-colored urine has been noted. This may be a sign of a serious liver issue, and this symptom should be reported to a healthcare provider without delay.

Q: Can Ponac cause skin reactions or rashes?

A: Yes, common side effects include general skin rash or itching. Additionally, regulatory warnings highlight that severe and potentially fatal skin reactions, such as Stevens-Johnson Syndrome (SJS), can occur, and official information instructs that treatment should be discontinued and medical help sought at the first sign of a rash or hypersensitivity.

Q: What are the signs of an allergic reaction to Ponac that I should watch out for?

A: If signs of an allergic reaction occur, official warnings state that the medication should be discontinued immediately and emergency medical help sought. These signs include hives, difficulty breathing, swelling of the face, tongue, or throat, or redness and irritation of the eyes.

Q: Can Ponac interact with herbal remedies like St. John's Wort?

A: Official drug labels focus primarily on prescription drug interactions. While St. John’s Wort is not always explicitly named, it is known to affect the metabolism of many medicines. Therefore, it is necessary to disclose all herbal and complementary products to a healthcare provider before use.

Q: How does Ponac affect blood clotting?

A: Ponac (mefenamic acid) works by temporarily inhibiting the function of platelets, the cells responsible for initiating blood clotting. This effect is short-lived and reversible, but it can prolong bleeding time and is why the drug carries warnings about increased risk of bleeding.

Q: Do people with asthma need to be cautious about taking Ponac?

A: Yes, Ponac is contraindicated (its use is strictly prohibited) for patients who have a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or other NSAIDs. This is due to the potential risk of triggering a severe and dangerous breathing condition called bronchospasm.

Q: Can Ponac be used to reduce fever?

A: Ponac (mefenamic acid) possesses antipyretic (fever-reducing) properties as part of its NSAID mechanism. However, its approved uses, or labeled indications, are specifically for the relief of acute pain and menstrual pain.

Q: Is there a maximum number of days or weeks Ponac is usually prescribed for?

A: Official prescribing information states that the duration of therapy for acute pain should generally not exceed 1 week (7 days). For the treatment of primary dysmenorrhea (menstrual pain), the duration is typically limited to 2 to 3 days.

Q: Are there any known issues with Ponac and driving or operating machinery?

A: Official information indicates that Ponac may cause side effects such as dizziness, drowsiness, or changes in vision. Official guidelines advise that caution should be exercised before performing tasks that require concentration, such as driving or operating machinery, if side effects like dizziness or drowsiness are experienced.

Q: Are there any dietary restrictions recommended while taking Ponac?

A: Regulatory documents strongly advise taking Ponac with food or milk to reduce the potential for irritation and side effects in the digestive system. Official information advises against the consumption of alcohol while taking this medication.

How should Ponac be stored and disposed of?

The storage and disposal of Ponac (Mefenamic Acid) must strictly follow official governmental instructions.

Required Storage Conditions

The medicine must be stored at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F), with permitted brief temperature excursions. The container must be kept tightly closed and protected from moisture and excessive heat to maintain product stability.

Disposal and Safety

All medicine must be stored out of the sight and reach of children.

Unused or expired product must be disposed of according to local requirements. The regulatory instructions explicitly state that the medicine must not be discarded via wastewater (flushed down the toilet) or placed in general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ponac found in:

A-Z Index: